Landos Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LABP research report →
Companylandosbiopharma.com
Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).
- CEO
- Gregory Oakes
- IPO
- 2021
- Employees
- 19
- HQ
- Blacksburg, VA, US
Price Chart
Valuation
- Market Cap
- $71.68M
- P/E
- -6.56
- P/S
- 0.00
- P/B
- 4.53
- EV/EBITDA
- -1.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.86%
- ROIC
- -71.49%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-21,935,000 · 42.26%
- EPS
- $-3.50 · 62.92%
- Op Income
- $-22,727,000
- FCF YoY
- 55.27%
Performance & Tape
- 52W High
- $22.94
- 52W Low
- $3.15
- 50D MA
- $20.19
- 200D MA
- $8.35
- Beta
- 0.14
- Avg Volume
- 27.04K
Get TickerSpark's AI analysis on LABP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 23, 24 | MAYLEBEN TIMOTHY M | sell | 1,800 |
| May 23, 24 | MAYLEBEN TIMOTHY M | sell | 1,800 |
| May 23, 24 | Girao Tiago | sell | 1,800 |
| May 23, 24 | Girao Tiago | sell | 1,800 |
| May 23, 24 | Girao Tiago | sell | 1,800 |
| May 23, 24 | Callori Fred | sell | 1,800 |
| May 23, 24 | Callori Fred | sell | 1,800 |
| May 23, 24 | Callori Fred | sell | 1,800 |
| May 23, 24 | Batycky Alka | sell | 3,600 |
| May 23, 24 | Adsett Roger | sell | 1,800 |
Our LABP Coverage
We haven't published any research on LABP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LABP Report →